A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Lee
Aptamer Sciences, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Cancer Center, Korea
Goyang-si, Gyeonggi-do, South Korea
Bo Hyun Kim, MD, PhDSang Myung Woo, MD, PhDRecruiting - Cha Bundang Medical Center
Seongnam, South Korea
Hong Jae Chon, MD, PhDRecruiting - Samsung Medical Center
Seoul, South Korea
Jung Yong Hong, MD, PhDRecruiting - Severance Hospital
Seoul, South Korea
Hye Ryun Kim, MD, PhD.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Mar 2025
- Primary completion
- 31 Dec 2027
- Completion
- 31 May 2028
- Last update posted
- 27 Mar 2026
- Registered enrollment
- 70
- Registry id
- NCT06687941
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.